New genetic test may help women with early breast cancer avoid unnecessary treatment
NCT ID NCT04916808
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 1,500 women with ductal carcinoma in situ (DCIS), a very early form of breast cancer, who have had breast-conserving surgery. Researchers want to see if a genetic test called DCISionRT helps doctors decide whether to add radiation or hormone therapy after surgery. The goal is to learn if the test leads to better, more personalized treatment plans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DCIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GenesisCare
Alexandria, New South Wales, 2015, Australia
-
Royal Melbourne Hospital
Parkville, Victoria, 3050, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One-Week radiation for breast cancer: MRI precision may cut side effects
- New test may help tailor treatment for early breast cancer
- One-Week radiation shows promise for breast cancer patients
- Could monitoring replace surgery for some breast lesions?
- Breast cancer overdiagnosis? landmark trial tests monitoring vs. surgery for Low-Risk DCIS
- Radiation-Free path for Low-Risk breast cancer patients?